News Releases

News & Events

News Releases

Dr. Martine Dehlinger-Kremer, Global Vice President Medical and Regulatory Affairs for Synteract, to Speak on Pediatric Research at Pharmig/OKIDS Conference in Vienna

Presentation addresses the challenges and opportunities in pediatric clinical research

SAN DIEGO – Nov. 14, 2014 – Dr. Martine Dehlinger-Kremer, who is chair of the pediatric working group for EUCROF (European Contract Research Organization Federation) as well as global vice president of medical and regulatory affairs for Synteract, a full-service, international contract research organization (CRO), will present on the benefits of pediatric networks from the CRO perspective on Nov. 18, 2014 in Vienna at the Pharmig/OKIDS Conference.

Pharma companies meet with several challenges in developing clinical trials for pediatric research, among them the limited number of children with specific diseases, fear of parents to allow their children to participate in clinical trials, and the strict inclusion and exclusion criteria that must govern children’s drug trials. Through Dr. Dehlinger-Kremer’s address, they will learn about the new opportunities for networks that may assist them, from the initial pediatric development plan, e.g, support for the PIP preparation, through study development, feasibility, site identification, and recruitment of patients for pediatric trials.

See Synteract's full schedule of events online, and follow its social channels on LinkedIn and Twitter for articles and updates on the regulatory landscape.

About Synteract (                                       

Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and in more than 50 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy and Intelligent Clinical Development platform (ICD+), Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data so clients get to decision points faster.

Beth Walsh


Contact Synteract

Tell us how to stay in touch with you: